Live In Play

Live In Play®

Updated: 21-Jul-22 06:56 ET

DGX: Quest Diagnostics beats by $0.10, beats on revs; guides FY22 EPS above consensus, revs above consensus (134.84)

Reports Q2 (Jun) earnings of $2.36 per share, $0.10 better than the S&P Capital IQ Consensus of $2.26; revenues fell 3.8% year/year to $2.45 bln vs the $2.34 bln S&P Capital IQ Consensus.
Co issues upside guidance for FY22, sees EPS of $9.55-9.95 vs. $9.30 S&P Capital IQ Consensus. This up from $9.00-9.50; sees FY22 revs of $9.50-9.75 bln vs. $9.4 bln S&P Capital IQ Consensus. This is up from $9.2-9.5 bln.